CA 15-3: Uses and limitation as a biomarker for breast cancer

This publication has 71 references indexed in Scilit:

• Mucins in cancer: function, prognosis and therapy
  Nature Reviews Cancer, 2009
• International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy
  JNCI: Journal of the National Cancer Institute, 2009
• Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
  Annals of Oncology, 2009
• Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma Cells
  Cancer Research, 2009
• Serum HER‐2/neu and relative resistance to trastuzumab‐based therapy in patients with metastatic breast cancer
  Cancer, 2008
• Follow-up after breast cancer
  BMJ, 2008
• American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
  Journal of Clinical Oncology, 2007
• Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA
  European Journal of Cancer, 2004
• Tumor Necrosis Factor-α Converting Enzyme/ADAM 17 Mediates MUC1 Shedding
  Journal of Biological Chemistry, 2003
• The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers
  European Journal of Cancer, 1999